Prices delayed ≤15 min
AI Analysis Summary
AbbVie Inc. at a Glance: What the Business Does AbbVie Inc. (ABBV) operates in the healthcare sector, specifically in the drug manufacturing industry, where it focuses on discovering, developing, manufacturing, and selling pharmaceuticals globally. The company is well-known for its flagship product, HUMIRA, which is widely prescribed for autoimmune and intestinal Behçet's diseases. In addition to HUMIRA, AbbVie has introduced innovative therapies such as SKYRIZI for moderate to severe plaque psoriasis and RINVOQ, a JAK inhibitor for rheumatoid arthritis. With a workforce of approximately 55,000 employees and a headquarters in North Chicago, IL, AbbVie has established a significant market presence. Its competitive advantages stem from a strong portfolio of proprietary drugs and a robust pipeline that promises future growth. As the industry continues to evolve, AbbVie’s focus on research and development positions it uniquely within the drug manufacturing landscape. Breaking Down ABBV's Financials: Revenue, Margins & EPS AbbVie has demonstrated a solid revenue trajectory, reporting revenue of $61.16 billion for the latest fiscal year, an increase from $56.33 billion the previous year, reflecting a year-over-year growth of 8.6%. This upward trend in revenue is notable, especially considering the three-year trajectory, which shows a steady increase from $54.32 billion in 2021 to the current figure. The company maintains impressive profit margins, with a gross margin of 83.7%, which translates to a gross profit of $51.20 billion. Operating income stands at $21.21 billion, yielding an operating margin of 34.7%. However, net income is recorded at $4.23 billion, resulting in a net margin of 6.9%, indicating some challenges in the bottom line compared to revenue growth. The earnings per share (EPS) is reported at $2.38, reflecting a slight decline in EPS growth of 0.8% year-over-year, which investors may want to monitor as they assess future profitability. ABBV Balance Sheet Check: Debt, Cash & Liquidity A closer look at AbbVie's balance sheet reveals a total asset figure of $133.96 billion against total liabilities of $137.19 billion, resulting in negative shareholders' equity of $3.27 billion. The company's debt levels are substantial, with total debt amounting to $69.07 billion, while cash reserves stand at only $5.23 billion. This leads to a net debt position of $63.84 billion, which raises concerns about financial leverage. The current ratio is 0.67, indicating that AbbVie may face challenges in covering its short-term obligations, as it holds less than a dollar of current assets for every dollar of current liabilities. Overall, while AbbVie has a strong revenue-generating capacity, its balance sheet reflects a leveraged position that warrants caution among investors. Where Does ABBV's Cash Go? A Capital Allocation Review AbbVie has demonstrated strong operating cash flow, generating $19.03 billion, which supports its capital allocation decisions. The company reported a free cash flow of $17.82 billion, indicating its ability to generate cash after capital expenditures, which were recorded at $1.21 billion. This substantial free cash flow allows AbbVie to reinvest in research and development, crucial for maintaining its competitive edge in the pharmaceutical industry. Additionally, the company has undertaken stock buybacks amounting to $980 million, reflecting a commitment to returning value to shareholders. However, the slight decline in free cash flow growth of 0.1% year-over-year may suggest the need for careful monitoring of cash management strategies going forward. Overall, AbbVie's capital allocation appears focused on sustaining growth while balancing shareholder returns. ABBV Valuation: Expensive, Cheap, or Fairly Priced? When analyzing AbbVie's valuation metrics, the company currently does not provide a P/E ratio or a PEG ratio, making traditional valuation comparisons challenging. However, its price-to-sales (P/S) ratio stands at 6.69, which is relatively high compared to industry standards, indicating that investors may have high growth expectations priced into the stock. The price-to-book (P/B) ratio is notably negative at -125.12, reflecting the company's negative shareholders' equity, which complicates traditional valuation assessments further. The dividend yield is currently at 0.75%, suggesting that while AbbVie does return some capital to shareholders, it may not be a primary attraction for income-focused investors. Given these valuation metrics, the current pricing of ABBV suggests that the market anticipates a strong growth trajectory, which investors should evaluate against the company's operational performance and market conditions. Catalysts Ahead: ABBV's Growth Outlook & Analyst Estimates Looking forward, AbbVie’s growth outlook is supported by its robust pipeline, which includes several promising therapies that are expected to drive revenue in the coming years. The company's recent revenue growth of 8.6% year-over-year signals a positive trajectory, although specific analyst estimates are currently unavailable to provide further clarity on future earnings projections. Factors such as market expansion opportunities and the potential for new product approvals will play a critical role in shaping AbbVie's growth narrative. Investors should keep an eye on upcoming clinical trial results and regulatory decisions, as these could serve as significant catalysts for stock performance. While the absence of specific forward estimates may limit immediate insights, the company's ongoing focus on innovation suggests a pathway for sustained growth. ABBV Investment Risks Worth Knowing About Investors considering AbbVie should be aware of several risks associated with the stock. The company's significant debt burden, with total debt at $69.07 billion, raises concerns about financial stability, particularly in a rising interest rate environment. Furthermore, net income has shown a slight decline of 1.2% year-over-year, which could indicate potential margin compression as competition increases in the pharmaceutical sector. Regulatory risks also loom large, as any changes in healthcare policies or drug approval processes could impact revenue streams. Additionally, with a beta of 0.35, AbbVie exhibits lower volatility compared to the broader market, suggesting that while it may be less sensitive to macroeconomic fluctuations, it is still not immune to industry-specific challenges. These factors highlight the importance of thorough risk assessment for potential investors. 2026 Outlook: Is AbbVie Inc. Stock Worth Owning? In synthesizing the information, AbbVie Inc. presents a mixed investment profile as of 2026. The company has shown a robust revenue growth trajectory and maintains strong operating cash flow, yet its significant debt levels and negative shareholders' equity raise red flags regarding its financial health. The innovative product pipeline and commitment to research and development may offer long-term growth potential, appealing to growth-oriented investors. However, the risks associated with debt and market competition necessitate a cautious approach. AbbVie may suit those willing to accept some risk in exchange for potential upside, particularly in a sector known for its volatility. Investors should closely monitor upcoming product launches, market conditions, and financial performance metrics to make informed decisions regarding ABBV stock.
About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat
Frequently Asked Questions about ABBV
AbbVie Inc. (ABBV): what does the company actually do?
AbbVie Inc. is deeply involved in the pharmaceutical sector, focusing on the discovery, development, manufacturing, and sales of a variety of drugs worldwide. Notably, the company is recognized for its flagship products like HUMIRA, which treats autoimmune conditions, and SKYRIZI, aimed at moderate to severe plaque psoriasis.
Is ABBV worth adding to a portfolio in 2026?
Considering AbbVie's revenue growth of 8.6% over the past year, there is a strong case for its potential in a diversified portfolio. However, the lack of a P/E ratio could raise questions for some investors about its valuation compared to peers in the healthcare sector.
What are AbbVie Inc.'s market cap and current trading price?
As of now, AbbVie Inc. has a market capitalization of approximately $406.42 billion, and its stock is trading at $229.98. This price is situated between its 52-week high of $244.81 and low of $164.39, reflecting a solid performance within that range.
Is ABBV a dividend-paying stock?
Yes, AbbVie Inc. does distribute dividends, currently offering $1.73 per share, which translates to a yield of 0.75%. This can be appealing for investors looking for income, although the yield may be considered modest compared to other dividend-paying stocks.
How does AbbVie Inc. stack up on profitability?
AbbVie demonstrates a net income of $4.23 billion with a net margin of 6.9%, indicating a reasonable level of profitability. Furthermore, the company's free cash flow stands at an impressive $17.82 billion, suggesting strong operational efficiency.
Is ABBV trading at a reasonable P/E multiple?
Currently, AbbVie does not have a P/E ratio available, which complicates direct valuation comparisons with other companies in the drug manufacturing sector. This absence of a P/E metric may suggest that investors should look at other valuation methods to assess its attractiveness.
Is AbbVie Inc. carrying a lot of debt?
AbbVie’s balance sheet appears to be relatively healthy, as the debt-to-equity ratio is not applicable, indicating that traditional debt metrics may not be available. Additionally, the company has a current ratio of 0.67, which suggests that it may face challenges in meeting short-term liabilities.
What's the 52-week high and low for ABBV?
The stock has experienced a 52-week high of $244.81 and a low of $164.39. Currently, at $229.98, it is positioned favorably within this range, and its 50-day moving average of $226.61 indicates a generally positive short-term trend.
Does ABBV behave more like a growth stock or a value stock?
With a revenue growth rate of 8.6%, AbbVie leans more towards being a growth stock, appealing to investors seeking expansion potential. However, the absence of EPS data complicates a comprehensive analysis of its growth versus value characteristics.
What's the biggest risk factor for ABBV investors?
One significant risk for AbbVie investors is its beta of 0.35, which indicates lower volatility compared to the market. However, this relative stability could be offset by competitive pressures in the healthcare sector and potential challenges in drug approvals.